Avirmax Biopharma Achieves a Major Milestone in Gene Therapy Clinical Trials
Avirmax Biopharma, headquartered in the San Francisco Bay Area, has proudly announced the completion of the first cohort of patient enrollment in its Phase I/IIa clinical trial for ABI-110. This gene therapy aims to treat Wet Age-related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV), two serious retinal diseases capable of causing significant vision loss. With the trial's initial phase successfully completed, Avirmax is on the verge of potentially transforming the treatment landscape for these conditions.
Dr. Shawn Liu, the CEO of Avirmax Biopharma, expressed enthusiasm for this accomplishment, stating, "We are thrilled to announce this significant milestone in the clinical investigation of ABI-110. We believe that ABI-110 has the potential to revolutionize the treatment landscape for patients suffering from Wet AMD and PCV." This sentiment is echoed by Dr. Roger A. Goldberg, the Principal Investigator for the trial. He reported no serious adverse events or dose-limiting toxicities among the initial three subjects, indicating a promising start towards a viable treatment option.
Currently, patients suffering from Wet AMD and PCV face frequent injections that often only provide temporary relief. ABI-110 seeks to change that narrative by offering a more durable solution by targeting the genetic underpinnings of these diseases. Aivirmax Biopharma utilizes its proprietary engineered capsid, AAV.N54, to efficiently deliver therapeutic genes directly to the macula retina through intravitreal injection. This innovative approach marks a significant advancement in gene therapy technology, making AAV.N54 the only engineered capsid capable of ensuring effective gene expression in the macula.
As the trial progresses, the focus will shift to evaluating the longer-term efficacy and safety of ABI-110. The Avirmax team is dedicated to refining its gene therapy technology to enhance patient outcomes and preserve vision. With ongoing research and clinical trials, Avirmax is paving the way for safer, more effective treatments not just for AMD, but also for a range of other retinal disorders, including dry AMD, glaucoma, and diabetic retinopathy.
About Avirmax Biopharma
Avirmax Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to developing next-generation gene therapies. With a strong emphasis on innovation, the company is committed to delivering safe, effective, and accessible gene therapies. Their goal is to improve patient outcomes, particularly for those with vision-threatening conditions. For more information about Avirmax and its ongoing projects, visit
Avirmax Biopharma's official website.
As Avirmax Biopharma moves forward, the implications of their efforts could be transformative, offering hope to patients who have long struggled with the burden of frequent treatments and the looming threat of vision loss. This milestone is just the beginning for a brighter future in retinal health.